Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Lyell Immunopharma Inc
LYELCurrent price
0.45 USD
-0.017 USD (-3.60%)
Last closed
0.48 USD
Company
www.lyell.com
ISIN
US55083R1041
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
137 922 848 USD
Yield for 12 month
-79.99 %
1Y
3Y
5Y
10Y
15Y
LYEL
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Address: 201 Haskins Way, South San Francisco, CA, United States, 94080
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
0.80 USDP/E ratio
–Dividend Yield
–Current Year
+61 000 USD
Last Year
+130 000 USD
Current Quarter
+11 000 USD
Last Quarter
+34 000 USD
Current Year
+61 000 USD
Last Year
+130 000 USD
Current Quarter
+11 000 USD
Last Quarter
+34 000 USD
Key Figures LYEL
1 year
3 years
5 years
10 years
EBITDA
-199 302 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-22.05 %
PEG Ratio
–
Return On Equity TTM
-66.10 %
Wall Street Target Price
0.80 USD
Revenue TTM
61 000 USD
Book Value
1.30 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-15.40 %
Dividend Yield
–
Gross Profit TTM
61 000 USD
Earnings per share
-1.31 USD
Diluted Eps TTM
-1.31 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics LYEL
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History LYEL
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio TTM
–
Last Split Date
–
Stock Valuation LYEL
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
1 938.09
Price Sales TTM
2 261.03
Enterprise Value EBITDA
0.25
Price Book MRQ
0.36
Financials LYEL
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators LYEL
For 52 weeks
0.39 USD
2.88 USD
50 Day MA
0.56 USD
Shares Short Prior Month
5 977 013
200 Day MA
0.97 USD
Short Ratio
6.55
Shares Short
5 711 632
Short Percent
2.60 %
BeatStart